研究人員發現逆轉肺部纖維化的潛在治療方法
Researchers discover potential treatment to reverse lung scarring
數十年來，肺纖維化一直被認為是一種不可逆轉的疾病。
For decades, pulmonary fibrosis has been considered an irreversible condition.
儘管目前的藥物如 nintedanib 和 pirfenidone 有助於減緩疾病進程，但它們無法修復已經造成的損傷。
While current medications like nintedanib and pirfenidone help slow down the disease, they cannot fix the damage that has already occurred.
透過標靶白血球介素-11（IL-11）等蛋白質，或抑制免疫細胞中的 YAP/TAZ 蛋白質，科學家已成功在實驗室模型中刺激了組織再生。
By targeting proteins like interleukin-11 (IL-11) or inhibiting the YAP/TAZ proteins in immune cells, scientists have successfully stimulated tissue regeneration in laboratory models.
目標是將這些療法推進到臨床試驗，為未來能解決結疤根本原因而非僅止於緩解症狀的療法鋪平道路。
The goal is to move these treatments into clinical trials, paving the way for future therapies that address the root cause of scarring rather than just managing symptoms.
